Authors: V Moreno García P Cejas M Blanco Codesido J Feliu Batlle J de Castro Carpeño C BeldaIniesta J Barriuso J J Sánchez J Larrauri M GonzálezBarón E Casado
Publish Date: 2009/03/04
Volume: 24, Issue: 7, Pages: 741-748
Abstract
Between July 1995 and May 2007 148 patients with primary rectal adenocarcinoma received neoadjuvant chemoradiotherapy followed by mesorectal excision Preoperative treatment included various protocols UFT and leucovorin 28 and oxaliplatinbased chemotherapy 72 Clinical and pathological variables were evaluated in relation to patient outcomesThirteen percent of patients achieved a complete pathologic response No response or minimal response as defined by Dworak Tumor Regression Grade 0/1 was observed in 30 patients 20 At a median followup of 37 months the 3year DFS and OS were 64 and 83 respectively Pretreatment serum carcinoembryonic antigen CEA level ≤ 25 ng/ml was associated with higher DFS 74 vs 53 p = 0018 higher complete pathologic responses 21 vs 9 p = 005 and less recurrences 24 vs 44 p = 0014The data suggest that a CEA level ≤ 25 ng/ml might be a predictor not only of tumor response as has been suggested before but also of DFS This finding could be useful in the future to predict individual risk and to develop more aggressive or alternative strategies
Keywords: